Authorized purpose: Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.
Clinical role
Automated volumetric measurement with adjunctive density and quality-assurance reporting.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Not a diagnostic aid; use only as adjunctive information to the MQSA-qualified physician's final density assessment. Compatible raw data and the accepted manufacturer/configuration list are required.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Raw For Processing digital mammograms or raw DBT projections, typically left/right CC and MLO views; compatible sources include images obtained with curved paddles. Version 3.2 adds Giotto Class 2D processing and improved Hologic tomosynthesis support.
Who uses it?Intended users: Healthcare professionals; the final density-category assessment is made by an MQSA-qualified interpreting physician.
What does the software produce?Output: Fibroglandular and total breast volumes, percentage volumetric breast density, BI-RADS fourth- or fifth-edition density category, average/maximum dense-tissue thickness, maximum dense volume over a square-centimeter region, density maps and quality metrics including dose/pressure; DICOM Secondary Capture scorecard and Mammography CAD Structured Report.
What is its most important limitation?Key limitation: Not a diagnostic aid; use only as adjunctive information to the MQSA-qualified physician's final density assessment. Compatible raw data and the accepted manufacturer/configuration list are required.
Clinical takeaway. Clinical role: Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.
Evidence takeaway. Evidence from the reviewed source record: Software verification/regression evidence supports the 3.2 modification; the reviewed epidemiology publication is contextual use of the product family.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provides volumetric breast density, BI-RADS fourth- or fifth-edition density categories and dose/pressure quality metrics from raw mammography or DBT data as adjunctive information for an MQSA-qualified physician's breast-composition assessment.
Raw For Processing digital mammograms or raw DBT projections, typically left/right CC and MLO views; compatible sources include images obtained with curved paddles. Version 3.2 adds Giotto Class 2D processing and improved Hologic tomosynthesis support.
Fibroglandular and total breast volumes, percentage volumetric breast density, BI-RADS fourth- or fifth-edition density category, average/maximum dense-tissue thickness, maximum dense volume over a square-centimeter region, density maps and quality metrics including dose/pressure; DICOM Secondary Capture scorecard and Mammography CAD Structured Report.
Not a diagnostic aid; use only as adjunctive information to the MQSA-qualified physician's final density assessment. Compatible raw data and the accepted manufacturer/configuration list are required.
Exact FDA submission
Checked 2026-09-05
The baseline ACR shorthand Scanner manufacturers: All is narrowed to the FDA summary's supported input configurations; universal scanner support is not inferred.
Software verification/regression evidence supports the 3.2 modification; the reviewed epidemiology publication is contextual use of the product family.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Software verification/regression evidence supports the 3.2 modification; the reviewed epidemiology publication is contextual use of the product family.
The exact summary does not report disease-detection sensitivity; the family epidemiology study is not a software accuracy validation.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
No disease-detection specificity for version 3.2 was established.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Volpara Imaging Software 3.2 Special 510(k) verification and validation
DesignSoftware unit and integration validation with repeated predicate tests for compatibility and software modifications.
PopulationSoftware verification dataset; clinical cohort size not reported in the summary.
Cadmium and volumetric mammographic density: A cross-sectional study in Polish women
DesignCross-sectional epidemiology study relating urinary cadmium to volumetric mammographic density.
Population517 women aged 40-60 undergoing screening mammography in Lodz, Poland; raw CC and MLO images analyzed with Volpara.
Scopeproduct family
Tested versionVolpara Imaging Software; version not specified in reviewed abstract
Samplen=517
IndependenceIndependence not established
PMID:32433664 · DOI:10.1371/journal.pone.0233369
Abstract reviewed. This is use of a measurement tool, not a sensitivity/specificity study or validation of version 3.2. No software-outcome claim is extracted.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Raw For Processing digital mammograms or raw DBT projections, typically left/right CC and MLO views; compatible sources include images obtained with curved paddles. Version 3.2 adds Giotto Class 2D processing and improved Hologic tomosynthesis support.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Receives raw mammography/DBT data and generates a DICOM Secondary Capture scorecard, density maps and a DICOM Mammography CAD Structured Report; DICOM 2016 testing is described.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact summary describes a Microsoft Azure-connected off-the-shelf virtual appliance and lists Windows/Linux operating environments.
Scope: Exact FDA submission. Refines the baseline On-premise label. The summary does not fully resolve hosting region, what crosses the Azure connection or current commercial topology.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Fibroglandular and total breast volumes, percentage volumetric breast density, BI-RADS fourth- or fifth-edition density category, average/maximum dense-tissue thickness, maximum dense volume over a square-centimeter region, density maps and quality metrics including dose/pressure; DICOM Secondary Capture scorecard and Mammography CAD Structured Report.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Fibroglandular and total breast volumes, percentage volumetric breast density, BI-RADS fourth- or fifth-edition density category, average/maximum dense-tissue thickness, maximum dense volume over a square-centimeter region, density maps and quality metrics including dose/pressure; DICOM Secondary Capture scorecard and Mammography CAD Structured Report.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact summary describes a Microsoft Azure-connected off-the-shelf virtual appliance and lists Windows/Linux operating environments.
Exact FDA submission
Checked 2026-09-05
Refines the baseline On-premise label. The summary does not fully resolve hosting region, what crosses the Azure connection or current commercial topology.
Receives raw mammography/DBT data and generates a DICOM Secondary Capture scorecard, density maps and a DICOM Mammography CAD Structured Report; DICOM 2016 testing is described.
The official Scorecard page combines density and risk information and states that Tyrer-Cuzick 8 risk modeling requires additional software purchase and is not available in all countries.
product family · checked 2026-09-05
Does not add risk modeling to the cleared indications of Volpara Imaging Software 3.2.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
20Fields reviewed
10Source classes checked
3Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored titles screened: 35913368 (ionizing radiation) and 34524273 (cigarette smoking) are density epidemiology leads without exact-version linkage in metadata; not promoted. PMID 32433664 abstract reviewed live and retained only as contextual product-family use. No trials stored. The current discovery snapshot contains 3 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, peer reviewed publication, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-05 - Exact product version
Checked 2026-10-25: the vendor-published US Master License and Services Agreement (v02-2024) says fees are set per customer in a Quotation, with no list price. The Scorecard product page already on file establishes no price. Federal award records found were aggregator listings, not a price for this cleared version. No price is stated.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Volpara Imaging Software reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact product version
The summary's description of a secure virtual host does not establish a current scoped security attestation or Azure data flow and retention controls.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact product version
The physician qualification is known; a version 3.2 training syllabus, duration and competency process were not established.
Monitoring: Not verified - checked 2026-09-05 - Exact product version
Density sanity checking is described for 3.2, but a site monitoring service or update acceptance program was not established. Editorial questions: confirm raw-image routing, supported paddles and correct scorecard/patient matching.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.